SAB Biotherapeutics
SABS
25 hedge funds and large institutions have $10.1M invested in SAB Biotherapeutics in 2024 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 6 reducing their positions, and 5 closing their positions.
19% more capital invested
Capital invested by funds: $8.48M → $10.1M (+$1.63M)
0% more funds holding
Funds holding: 25 → 25 (0)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
5.51% less ownership
Funds ownership: 34.04% → 28.53% (-5.5%)
17% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HWM
HB Wealth Management
Atlanta,
Georgia
|
+$423K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$41.7K |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$37.4K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$3.56K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.41K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
-$1.72M |
| 2 |
Millennium Management
New York
|
-$74K |
| 3 |
First Manhattan
New York
|
-$66.4K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$27.8K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$4.08K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
RI
26
RTW Investments
New York
| – | -$1.72M | -635,276 | Closed |
|
|
27
First Manhattan
New York
| – | -$66.4K | -24,577 | Closed |
|
|
28
Citadel Advisors
Miami,
Florida
| – | -$27.8K | -10,305 | Closed |
|
|
PGAM
29
Princeton Global Asset Management
Princeton,
New Jersey
| – | -$1.35K | -500 | Closed |
|
30
Barclays
London,
United Kingdom
| – | -$27 | -10 | Closed |
|
SABS Hedge Fund Activity: Q4 2024 in Review
25 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in SAB Biotherapeutics (SABS) for Q4 2024, worth a combined $10.1M — up 19% from $8.48M a quarter earlier.
Fund positioning in SABS was balanced in Q4 2024: 5 funds opened new positions, 5 closed out, 5 added to existing stakes and 6 trimmed.
The largest buyer was HB Wealth Management, adding an estimated $423K. The largest seller was RTW Investments, exiting entirely with an estimated $1.72M sold.
- 25 institutional investors held SAB Biotherapeutics (SABS) as of Q4 2024, unchanged from Q3 2024.
- Funds reported $10.1M of SAB Biotherapeutics stock for Q4 2024, up 19% quarter-over-quarter.
- 5 funds opened new SAB Biotherapeutics positions in Q4 2024 and 5 closed out, a net change of 0 holders.
- The largest SAB Biotherapeutics buyer in Q4 2024 was HB Wealth Management, an estimated $423K added.
- The largest SAB Biotherapeutics seller in Q4 2024 was RTW Investments, an estimated $1.72M sold.
Based on aggregated 13F filings for Q4 2024.